Abera Bioscience

Abera Bioscience EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Abera Bioscience (ABERA.SL) as of Oct 19, 2026 is -37.15 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -9.84 % — a change of 277.44% (lower).

EBIT/Assets

-37.15 %

YoY

277.44%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Abera Bioscience is 2025 -37.15 % . Operating Income to Assets Ratio (EBIT/Assets) of Abera Bioscience was 2024 -9.84 % . It decreases by 277.44% lower compared to the previous year.

The Abera Bioscience EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-108.81 SEK
Jan 1, 2019
-50.57 SEK
Jan 1, 2020
-122.79 SEK
Jan 1, 2021
-29.21 SEK
Jan 1, 2022
-99.39 SEK
Jan 1, 2023
-181.02 SEK
Jan 1, 2024
-9.84 SEK
Jan 1, 2025
-37.15 SEK
The Abera Bioscience EBIT/Assets history
YEAREBIT/AssetsYoY
-37.15 %+277.44%
-9.84 %-94.56%
-181.02 %+82.13%
-99.39 %+240.28%
-29.21 %-76.21%
-122.79 %+142.83%
-50.57 %-53.53%
-108.81 %+89.38%
-57.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

Operating Income to Assets Ratio (EBIT/Assets) of Abera Bioscience is -37.15 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Abera Bioscience changed from -9.84 % to -37.15 %, representing a 277.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Abera Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Abera Bioscience

All Key Metrics — Abera Bioscience